Remifemin Preventing the Climacteric Symptoms in Breast Cancer
Mo kle
Abstrè
Deskripsyon
Ovarian function suppression (OFS) or protection has been studied widely in breast cancer. As an common drug in clinic, LHRH-a is an important method for OFS in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting. The climacteric symptoms caused by LHRH-a are often and prominent, which is a common clinical problem. Remifemin (cimicifuga racemosa / black cohosh) is effective in climacteric symptoms as a hormone replacement treatment, some research concluded that it is also safe in breast cancer patients who are postmenopausal or taking tamoxifen suffering from climacteric symptoms. While in China, more than 2/3 breast cancer patients are pre/peri-menopause, and some part of them should take OFS as an hormone treatment. OFS can cause sever climacteric symptoms in a short time. The investigators aim to estimate the effect and safety of Remifemin in climacteric symptoms caused by OFS in breast cancer.
Dat
| Dènye verifye: | 06/30/2018 |
| Premye Soumèt: | 10/14/2017 |
| Enskripsyon Estimasyon Soumèt: | 11/06/2017 |
| Premye afiche: | 11/12/2017 |
| Dènye Mizajou Soumèt: | 07/03/2018 |
| Dènye Mizajou afiche: | 07/05/2018 |
| Dat aktyèl kòmanse etid la: | 01/03/2017 |
| Dat Estimasyon Prensipal Estimasyon an: | 11/26/2017 |
| Dat estime fini etid la: | 01/29/2018 |
Kondisyon oswa maladi
Entèvansyon / tretman
Drug: Remifemin intervention
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| Experimental: Remifemin intervention Using Remifemin during LHRH-a treatment in breast cancer | Drug: Remifemin intervention Remifemin 0.2g po bid*12 weeks at the beginning of the LHRH-a treatment |
| No Intervention: Control No intervention during LHRH-a treatment in breast cancer |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 18 Years Pou 18 Years |
| Sèks ki kalifye pou etid | Female |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: 1. provision of informed consent 2. clinical stage I~IIIC 3. histologically proven invasive breast cancer 4. women defined as premenopausal according to NCCN guideline 5. plan to accept the LHRH-a as endocrine treatment or ovarian function protection Exclusion Criteria: 1. clinical evidence of metastatic disease 2. bilateral oophorectomy 3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements 4. patients who accepted anti-cancer treatment before 5. previous hormonal therapy as adjuvant treatment for non-cancer disease 6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied 7. treatment with a non-approved or experimental drug during 1 month before entry into the study 8. history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin) 9. leukopenia and/or thrombocytopenia 10. history of ocular fundus diseases 11. history of thromboembolic diseases 12. history of osteoporotic fractures |
Rezilta
Mezi Rezilta Prensipal yo
1. Kupperman Item (KMI) [3 months after treatment]
Mezi Rezilta Segondè
1. Disease free survival [2 years]
